AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted.
Pixabay/Public Domain
Leerink added “very strong current business performance” to its list of considerations, emphasizing Skyrizi’s ongoing expansion in spite of its already substantial market dominance.
The firm forecasts that as pressure from Humira biosimilars decline, Abbvie’s total top-line growth will pick up speed, rising from 8% in 2025 to 11% in 2026. Though no specifics were given, Leerink also identified three oncology pipeline candidates that would eventually contribute significantly to Abbvie’s revenue.
AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company that specializes in developing, manufacturing, and marketing therapies for complicated and chronic illnesses. Its next-generation immunology medications, Rinvoq and Skyrizi, continue to drive growth.
While we acknowledge the potential of ABB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at Insider Monkey.